Investing in the science that defines tomorrow’s medicine

Luma Group funds early and mid-stage biotechnology companies. Our approach integrates AI-driven analysis, scientific rigor, and an advisor network spanning research, clinical practice, and industry leadership.

Explore Portfolio

First-principles science

We partner with teams that have deep biological conviction—grounded in data and clear paths to translation that can become durable, scalable patient impact.

Accelerated insight with LABI

Our AI system speeds up how we analyze data, validate breakthroughs, and uncover real potential.

Hands-on industry leadership

We go beyond financial capital to work with founders that are innovating at the edge of innovative healthcare solutions.

Breakthrough science.
Disciplined execution.

We back teams translating breakthrough biology into therapies, diagnostics, and medical devices that can scale impact for patients.

Explore Portfolio

Research, analysis, and updates from our network

Articles, whitepapers, and expert commentary.

See More Insights
Whitepapers

From Blunt Sedation to Precise Disease Control: Insights into Anti-Seizure Medications

Living with epilepsy can feel like walking in a minefield: patients often feel like they need to tiptoe through their lives, fearful that any misstep or obscure catalyst can trigger a (potentially deadly) seizure. In the non-epileptic brain, neuron ensembles operate with one another in precise and synchronized coordination, giving rise to normal cognition, perception, and movement. In many epilepsy cases, patients develop seizures after an injury or other insult (e.g., traumatic brain injury, stroke, tumors, etc.) induces a structural malformation in the brain, serving as the source of abnormal discharges between neurons that manifest as seizures. In other cases, mutations in a variety of genes can disrupt the normal balance between excitation and inhibition within neurons, representing direct genetic causes of epilepsy.

See More
Podcasts
•External link

Reimagining Chronic Care: A Conversation with Ritish Patnaik of Curve Biosciences

Dr. Themasap Khan, co-founder and partner, sat down with Ritish Patnaik, CEO and co-founder of Curve Biosciences, to discuss his career, the journey to co-founding Curve, the company’s transformative impact, and what’s next. Beyond delving into Curve’s groundbreaking science, Ritish shares leadership insights and advice for navigating the world of biotech, explaining how his life experience pushed him to biotech.

See More
Whitepapers

Decoding Aging: Breakthroughs, Challenges and the Future of Longevity Drug Development

For centuries, humans have sought to understand—and potentially slow, halt or reverse—the aging process. Recent advances in molecular and cellular biology have begun to illuminate the core hallmarks and drivers of aging, providing a foundational framework for new therapeutic approaches. While some of these therapies have not fulfilled their initial promise, others have achieved remarkable progress, and ongoing clinical trials may pave the way for a new class of longevity drugs. Still, despite growing optimism, the journey toward regulatory approval and widespread adoption of these treatments presents a unique set of challenges that must be navigated carefully.

See More